Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · BioAge Labs, Inc. (BIOA)

BioAge Labs Q2 net loss widens to $26.1 million as R&D spending rises

Negative Impact 3 of 5 earnings Written later

BioAge Labs reported second quarter 2026 results with a net loss of $26.1 million, or $0.58 per share, up from $21.6 million, or $0.60 per share, a year earlier. Collaboration revenue was flat at $2.4 million, while research and development expenses rose to $24.4 million, driven mainly by the QUELL-CV trial of BGE-102. The company had about $381.3 million in cash, cash equivalents, and marketable securities at June 30, 2026, and said that is enough to fund operations through 2029.

Key points

  • Net loss was $26.1 million for the quarter ended June 30, 2026, versus $21.6 million a year earlier; loss per share was $0.58 versus $0.60.
  • Research and development expenses rose $4.6 million to $24.4 million, mainly from a $7.9 million increase in BGE-102 program costs tied to QUELL-CV.
  • General and administrative expenses were $7.4 million, compared with $7.3 million a year earlier.
  • Cash, cash equivalents, and marketable securities totaled about $381.3 million as of June 30, 2026, which the company says will fund operations through 2029.

The filing

CompanyBioAge Labs, Inc. (BIOA)
Form8-K, current report
Filed with the SECAug 5, 2026, 4:55 PM ET
Accession number0001193125-26-335368

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.